Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117


Associations Between Glycemic Control, Depressed Mood, Clinical Depression, and Diabetes Distress Before and After Insulin Initiation: An Exploratory, Post Hoc Analysis.

Ascher-Svanum H, Zagar A, Jiang D, Schuster D, Schmitt H, Dennehy EB, Kendall DM, Raskin J, Heine RJ.

Diabetes Ther. 2015 Jul 10. [Epub ahead of print]


Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis.

Fu H, Cao D, Boye KS, Curtis B, Schuster DL, Kendall DM, Ascher-Svanum H.

Diabetes Ther. 2015 Jul 5. [Epub ahead of print]


Cognitive and Functional Decline in Patients With Mild Alzheimer Dementia With or Without Comorbid Diabetes.

Ascher-Svanum H, Chen YF, Hake A, Kahle-Wrobleski K, Schuster D, Kendall D, Heine RJ.

Clin Ther. 2015 Jun 1;37(6):1195-205. doi: 10.1016/j.clinthera.2015.01.002. Epub 2015 Feb 9.


Does participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?

Montgomery W, Treuer T, Ye W, Xue HB, Wu SH, Liu L, Kadziola Z, Stensland MD, Ascher-Svanum H.

Neuropsychiatr Dis Treat. 2014 Jul 10;10:1287-96. doi: 10.2147/NDT.S60246. eCollection 2014.


Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection.

Ascher-Svanum H, Novick D, Haro JM, Bertsch J, McDonnell D, Detke H.

Neuropsychiatr Dis Treat. 2014 Jun 20;10:1125-31. doi: 10.2147/NDT.S61409. eCollection 2014.


Early discontinuation and restart of insulin in the treatment of type 2 diabetes mellitus.

Ascher-Svanum H, Lage MJ, Perez-Nieves M, Reaney MD, Lorraine J, Rodriguez A, Treglia M.

Diabetes Ther. 2014 Jun;5(1):225-42. doi: 10.1007/s13300-014-0065-z. Epub 2014 Apr 30.


Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia.

Detke HC, Weiden PJ, Llorca PM, Choukour M, Watson SB, Brunner E, Ascher-Svanum H.

J Clin Psychopharmacol. 2014 Aug;34(4):426-34. doi: 10.1097/JCP.0000000000000140.


Characteristics of patients misdiagnosed with Alzheimer's disease and their medication use: an analysis of the NACC-UDS database.

Gaugler JE, Ascher-Svanum H, Roth DL, Fafowora T, Siderowf A, Beach TG.

BMC Geriatr. 2013 Dec 19;13:137. doi: 10.1186/1471-2318-13-137.


The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial.

Chen L, Johnston JA, Kinon BJ, Stauffer V, Succop P, Marques TR, Ascher-Svanum H.

BMC Psychiatry. 2013 Nov 28;13:320. doi: 10.1186/1471-244X-13-320.


Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study.

Ascher-Svanum H, Novick D, Haro JM, Bertsch J, McDonnell D, Detke H.

BMC Psychiatry. 2013 Sep 16;13:224. doi: 10.1186/1471-244X-13-224.


The personal, societal, and economic burden of schizophrenia in the People's Republic of China: implications for antipsychotic therapy.

Montgomery W, Liu L, Stensland MD, Xue HB, Treuer T, Ascher-Svanum H.

Clinicoecon Outcomes Res. 2013 Aug 14;5:407-18. doi: 10.2147/CEOR.S44325. eCollection 2013.


Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia.

Chen L, Ascher-Svanum H, Lawson A, Stauffer VL, Nyhuis A, Haynes V, Schuh K, Kinon BJ.

Neuropsychiatr Dis Treat. 2013;9:815-22. doi: 10.2147/NDT.S43574. Epub 2013 Jun 14.


Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited.

Ascher-Svanum H, Weiden P, Nyhuis AW, Faries DE, Stauffer V, Kollack-Walker S, Kinon BJ.

Clin Schizophr Relat Psychoses. 2014 Jul;8(2):84-90, 90A. doi: 10.3371/CSRP.ASWE.022213.


Predicting a 'combined treatment outcome' in chronic schizophrenia: the role of demographics, symptomatology, functioning and subjective well-being.

Naber D, Kollack-Walker S, Chen J, Stauffer VL, Kinon BJ, Case M, Ascher-Svanum H, Kapur S, Kane JM.

Pharmacopsychiatry. 2013 May;46(3):114-9. doi: 10.1055/s-0032-1331703. Epub 2013 Jan 4.


Comparing symptom response among antipsychotic medications in CATIE.

Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH.

J Clin Psychopharmacol. 2013 Feb;33(1):123-6. doi: 10.1097/ No abstract available.


Comparing Symptom Response Among Antipsychotic Medications in CATIE.

Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH.

J Clin Psychopharmacol. 2012 Dec 28. [Epub ahead of print] No abstract available.


Empirically driven definitions of "good," "moderate," and "poor" levels of functioning in the treatment of schizophrenia.

Ascher-Svanum H, Novick D, Haro JM, Aguado J, Cui Z.

Qual Life Res. 2013 Oct;22(8):2085-94. doi: 10.1007/s11136-012-0335-z. Epub 2012 Dec 14.


Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study.

Haynes VS, Zhu B, Stauffer VL, Kinon BJ, Stensland MD, Xu L, Ascher-Svanum H.

BMC Psychiatry. 2012 Dec 5;12:222. doi: 10.1186/1471-244X-12-222.


Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial.

Faries D, Ascher-Svanum H, Phillips G, Nyhuis AW, Sugihara T, Stauffer V, Kinon BJ.

BMC Med Res Methodol. 2012 Sep 13;12:142. doi: 10.1186/1471-2288-12-142.


Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation.

Matza LS, Phillips GA, Revicki DA, Ascher-Svanum H, Malley KG, Palsgrove AC, Faries DE, Stauffer V, Kinon BJ, Awad AG, Keefe RS, Naber D.

Patient Prefer Adherence. 2012;6:521-32. doi: 10.2147/PPA.S25635. Epub 2012 Jul 13.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk